Skip to main content
. Author manuscript; available in PMC: 2020 Mar 1.
Published in final edited form as: Mol Cancer Ther. 2019 Jul 11;18(9):1577–1586. doi: 10.1158/1535-7163.MCT-18-1386

Figure 1. ERG aberrant expression promotes resistance to PI3K and AR targeted therapy.

Figure 1.

A) Waterfall plots for proportional change in tumor volume in Ptenlox/lox (n=4) and ERG Ptenlox/lox mice (n=4) treated with BEZ235 (30mg/kg/day) and MDV3100 (30mg/kg/day). B) Representative MRI images of the ERG Ptenlox/lox mice pre- and post-treatment. C) Tumor volume measurements for ERG Ptenlox/lox tumor grafts (n=10 per group) treated with vehicle, castration+MDV3100, BEZ235, and castration+MDV3100+Bez235. D) Western blot confirming PI3K pathway target inhibition following acute treatment with BEZ235. E) AR immunohistochemistry showing cytoplasmic sequestering following combined PI3K/AR inhibition. F) qRT-PCR of canonical AR target genes across the treatment groups (3 tumors per group) demonstrates maintenance of AR target gene expression despite complete androgen blockade.